CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The new online Learning Center with new content can still be found under the “Training” folder on ...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...